InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc.

Company profile

• Business focus: Pharmaceutical drug development company developing proprietary small-molecule drug candidates that are preferential signaling ligands of the endocannabinoid system (CB1 and CB2 receptors) and other disease-relevant targets.

Pipeline and programs

• INM-901: Small-molecule candidate for Alzheimer’s disease. Acts as a preferential signaling agonist for CB1/CB2 with additional PPAR signaling effects. Intended to reduce neuroinflammation and support neuroprotection.
• INM-089: Small-molecule analog for dry age-related macular degeneration (dry AMD). Designed to provide retinal neuroprotection and improve retinal tissue integrity.
• INM-755 (cannabinol, CBN) cream: Topical product candidate for Epidermolysis Bullosa (EB). CB1/CB2 agonist with CB2 preference, focused on itch relief and wound-related symptoms.

Manufacturing approach

• Uses traditional chemical synthesis and biosynthesis methods.
• Employs a proprietary IntegraSyn integrated manufacturing approach to diversify production methods and potentially reduce costs.

Current corporate status and activities

• BayMedica wind-down: On March 4, 2026, InMed’s board ratified the wind-down and exit of BayMedica’s commercial operations. By June 30, 2026, BayMedica had wound down all operating activities; two remaining employees departed by July 31, 2026; a commercial lease ends at the end of August 2026. InMed’s remaining activities are focused on preclinical development of INM-901, INM-089, and INM-755. No significant resources are planned for further commercial development unless additional financing is obtained.
• Proposed merger with Mentari Therapeutics: InMed has referenced a proposed merger transaction with Mentari Therapeutics, Inc. Completion of the merger depends on financing and closing conditions, and there is no assurance the merger will be consummated.
• Development posture if merger is not consummated: Priorities will remain subject to financing and include advancing IND-enabling studies, manufacturing scale-up, regulatory planning, and potential initiation of Phase 1 trials for INM-901 and INM-089 in 2027, depending on regulatory feedback and available funding.

Employees and resources

• As of September 1, 2026 (inclusive of management): 6 full-time employees.
• The company also engages a number of consultants for program and operational support.

Revenue and income

• BayMedica was the company’s revenue-generating segment; its commercial operations have been wound down and there is no ongoing commercial operation revenue as of June 30, 2026.
• The company has incurred losses since inception and expects to incur losses in the future.

Intellectual property and patents (as of August 2026)

• InMed patent portfolio
  • 13 patent families covering cannabinoid and neuroprotection concepts, including INM-901, INM-089, INM-755, and related technologies.
  • Early patent expiries generally in the 2037–2043 window if granted; filings include US, AU, JP, EP, IN, IL, MX, CA, CN, SG, and others, with several patents granted and others pending.
• BayMedica patent portfolio
  • 8 patent families related to recombinant production systems, cannabinoid analogs and methods, yeast-based production for cannabinoids, and related manufacturing processes.
  • Expected expiries for granted patents typically around 2038–2042; filings include AU, US, JP, CN, IL, IN, MX, EP, CA, and others.
• Ownership and scope: InMed owns the InMed patent families; BayMedica owns its patent families. The combined portfolios cover delivery technologies, manufacturing processes for cannabinoids, and compositions and methods for treating neuronal disorders with cannabinoids.

Regulatory and compliance context

• Development activities are regulated by U.S. and international authorities, including FDA requirements for INDs and NDAs and relevant foreign regulatory frameworks.
• Product candidates containing cannabinoids implicate controlled-substance regulations and related import/export controls.
• Clinical development requires compliance with cGMP and other manufacturing standards and must address anti-kickback, privacy, and other applicable laws in relevant jurisdictions.

Risk context (summary)

• All three current product candidates are in early stages, and there is no assurance of regulatory approval or commercial viability.
• The wind-down of BayMedica introduces liquidity and operational uncertainties. Continued operations depend on securing additional financing or completing strategic transactions.
• The company emphasizes the need for capital to fund IND-enabling studies, manufacturing, regulatory work, and potential clinical trials.

If you’d like, I can provide a compact program snapshot for INM-901, INM-089, and INM-755.